De Wit R, Kulkarni GS, Uchio E, et al. Pembrolizumab for High-Risk (HR) Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial. ESMO 2018, abstract 864O.
Three-year Safety of Radium-223 in Patients with mCRPC and Symptomatic Bone Metastases
jul 2017 | Uro-oncologie